SJEPD030391_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 9.67
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.67242468
- umap2_2d
- 1.439456351
- umap1_3d
- -0.362231262
- umap2_3d
- 3.829504811
- umap3_3d
- -3.111783021
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.560
- OXIDATIVE_PHOSPHORYLATION+0.510
- PROTEIN_SECRETION+0.510
- G2M_CHECKPOINT+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- MTORC1_SIGNALING+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.410
- DNA_REPAIR+0.390
- ADIPOGENESIS+0.300
Top 10 suppressed
- KRAS_SIGNALING_DN-0.340
- MYOGENESIS-0.310
- WNT_BETA_CATENIN_SIGNALING-0.250
- APICAL_JUNCTION-0.210
- HEDGEHOG_SIGNALING-0.210
- APICAL_SURFACE-0.170
- ESTROGEN_RESPONSE_EARLY-0.120
- IL6_JAK_STAT3_SIGNALING-0.010
- NOTCH_SIGNALING-0.010
- XENOBIOTIC_METABOLISM-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.932 |
| 2 | BS_2EN3X6HB | high-grade glioma | — | 0.921 |
| 3 | TCGA-C4-A0F0-01A-12R-A10U-07 | — | — | 0.909 |
| 4 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.907 |
| 5 | SJEPD032054_D1.RNA-Seq | EPN | Supratentorial EPN | 0.904 |
| 6 | 54B7F258-FE9A-4EFE-87FB-465D587B1170 | — | — | 0.898 |
| 7 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.891 |
| 8 | BS_1A6MQ9ZA | high-grade glioma | — | 0.890 |
| 9 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.889 |
| 10 | BS_MT15SGJN | EPN | Supratentorial EPN | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |